Qin Zi-Ke, Yang Jian-An, Zeng Mu-Sheng, Zhou Fang-Jian, Han Hui, Liu Zhuo-Wei, Yu Shao-Long, Li Yong-Hong, Chen Zhuang-Fei
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
Ai Zheng. 2008 Dec;27(12):1327-30.
BACKGROUND & OBJECTIVE: At present, the molecular mechanisms of development and progression of bladder cancer are still poorly understood. This study was to explore the expression and significance of Bmi-1 in bladder cancer, and analyze its correlations to clinicopathologic features and prognosis of bladder cancer.
The expression of Bmi-1 protein in 137 specimens of bladder cancer and 30 specimens of normal bladder tissues was detected by SP immunohistochemistry, and its correlations to clinicopathologic features and prognosis of the patients were analyzed.
The positive rate of Bmi-1 protein was significantly higher in bladder cancer than in normal bladder tissues (54.3% vs. 16.7%, P<0.05). The positive rate of Bmi-1 protein was 20.6% in grade G1 bladder cancer, 54.3% in grade G2 bladder cancer, and 78.8% in grade G3 bladder cancer, with significant difference (P<0.05). It was significantly lower in superficial bladder cancer than in invasive bladder cancer (32.5% vs. 81.5%,P<0.05). The expression intensity of Bmi-1 was related to tumor size, classification, TNM stage and prognosis (P<0.05), but not to tumor number and tumor recurrence (P>0.05). The patients were followed up for 44-86 months, with a median of 66 months. The 5-year survival rate was significantly higher in superficial bladder cancer patients than in invasive bladder cancer patients (89.6% vs. 39.2%, P<0.05), and higher in Bmi-1-negative patients than in Bmi-1-positive patients (78.5% vs. 50.8%,P<0.05).
Bmi-1 protein is highly expressed in bladder cancer. Detecting Bmi-1 protein is helpful for diagnosis and prognostic evaluation of bladder cancer.
目前，膀胱癌发生发展的分子机制仍未完全明确。本研究旨在探讨Bmi-1在膀胱癌中的表达及意义，并分析其与膀胱癌临床病理特征及预后的相关性。
采用SP免疫组化法检测137例膀胱癌标本及30例正常膀胱组织中Bmi-1蛋白的表达，并分析其与患者临床病理特征及预后的相关性。
膀胱癌组织中Bmi-1蛋白阳性率显著高于正常膀胱组织（54.3%比16.7%，P<0.05）。G1级膀胱癌中Bmi-1蛋白阳性率为20.6%，G2级为54.3%，G3级为78.8%，差异有统计学意义（P<0.05）。浅表性膀胱癌中Bmi-1蛋白阳性率显著低于浸润性膀胱癌（32.5%比81.5%，P<0.05）。Bmi-1表达强度与肿瘤大小、分级、TNM分期及预后相关（P<0.05），但与肿瘤数目及肿瘤复发无关（P>0.05）。患者随访44~86个月，中位随访时间66个月。浅表性膀胱癌患者5年生存率显著高于浸润性膀胱癌患者（89.6%比39.2%，P<0.05），Bmi-1阴性患者5年生存率高于Bmi-1阳性患者（78.5%比50.8%，P<0.05）。
Bmi-1蛋白在膀胱癌中高表达。检测Bmi-1蛋白有助于膀胱癌的诊断及预后评估。
